Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021357 | 1.00 | MME (0.54) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL157547 | 0.88 | MME (0.61) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL8651835 | 0.86 | SLC7A5 (0.56) | MMESLC7A5NAALAD2L3MBTL1FOLH1 | |
| SCHEMBL5389540 | 0.85 | MME (0.57) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL5694618 | 0.85 | GNPAT (0.58) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL93439 | 0.85 | GNPAT (0.58) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL93440 | 0.85 | GNPAT (0.58) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL412958 | 0.85 | GNPAT (0.58) | MMEALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL27197703 | 0.83 | GNPAT (0.57) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL30566993 | 0.81 | MME (0.56) | MMENPSR1CYP1A2NAALAD2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096246-A1 | SEQUENCE-DEFINED HETEROPOLYMER BACKBONES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-118005913-A | Block copolymer with cell membrane pore-forming property and preparation method and application thereof | 四川大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240124910-A1 | RIBOSOME-MEDIATED POLYMERIZATION OF NOVEL CHEMISTRIES | NORTHWESTERN UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| WO-2022173627-A2 | RIBOSOME-MEDIATED POLYMERIZATION OF NOVEL CHEMISTRIES | NORTHWESTERN UNIVERSITY (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-1740581-B1 | 2, 4, 6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-08-22 | — | — | EP | disclosed |
| US-7968571-B2 | 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease | Merck, Sharp & Dohme, Corp. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1740581-A4 | 2, 4, 6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015233-A1 | 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-01-17 | — | — | US | disclosed |
| EP-1039804-A4 | METHOD FOR TREATING FIBROPROLIFERATIVE DISORDERS BY INHIBITORS OF PROTEIN HYDROXYLATION | CORNELL RES FOUNDATION INC (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1740581-A1 | 2, 4, 6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER\"S DISEASE | Merck and Co., Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-0831876-A1 | METHOD OF INHIBITING VIRAL REPLICATION IN EUKARYOTIC CELLS AND OF INDUCING APOPTOSIS OF VIRALLY-INFECTED CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0808103-A1 | PROTEIN HYDROXYLATION INHIBITORS FOR FIBROPROLIFERATIVE DISORDERS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5672681-A | Conformationally restricted mimetics of gamma turns and peptides containing the same | MOLECUMETICS, LTD. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5670155-A | Confomationally restricted mimetics of beta turns and beta bulges and peptides containing the same | MOLECUMETICS, LTD. (US) | 1997-09-23 | — | — | US | disclosed |
| WO-1996041639-A1 | METHOD OF INHIBITING VIRAL REPLICATION IN EUKARYOTIC CELLS AND OF INDUCING APOPTOSIS OF VIRALLY-INFECTED CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996022021-A1 | PROTEIN HYDROXYLATION INHIBITORS FOR FIBROPROLIFERATIVE DISORDERS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5475085-A | Unlimited array of peptides having reverse turn mimetics | MOLECUMETICS, LTD. (US) | 1995-12-12 | — | — | US | disclosed |
| EP-0656907-A1 | CONFORMATIONALLY RESTRICTED MIMETICS OF REVERSE TURNS AND PEPTIDES CONTAINING THE SAME | MOLECUMETICS, LTD. (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1994003494-A1 | CONFORMATIONALLY RESTRICTED MIMETICS OF REVERSE TURNS AND PEPTIDES CONTAINING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1993024518-A1 | DESIGN AND SYNTHESIS OF A CD4 BETA-TURN MIMETIC FOR INHIBITING THE BINDING OF HIV GP120 | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015233-A1 | 2,4,6-Substituted Pyridyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN2 | MME 83/4885ALPI 1309/4885PKM 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.